Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the ...
Amsterdam, The Netherlands, January 22, 2021 – Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the …